ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

There’s a New Way to Treat AFib - Here’s What You Should Know

By: NewsUSA

(NewsUSA) - Do you ever notice a flutter in your chest? Feel unusually tired even after a good night’s sleep? Get winded from walking up the stairs when that never used to happen? These little signs might not feel like a big deal, but they could point to something more serious: atrial fibrillation, or AFib.

AFib is the most common heart rhythm disorder in the world, affecting more than 60 million people.1 In the U.S. alone, over 12 million people are expected to be living with the condition by 2030.2

Yet, awareness remains surprisingly low. A nationally representative survey sponsored by Medtronic found that nearly half of Americans haven’t heard of AFib.3 Because symptoms can be mild or easy to brush off, many people don’t realize they may be at risk. But without proper diagnosis and treatment, AFib can lead to major health complications, including blood clots, stroke, and heart failure.4

Know the Symptoms of AFib

AFib occurs when the upper chambers of the heart (called the atria) beat irregularly and out of sync with the lower chambers. This disrupts the heart’s normal rhythm and reduces its ability to pump blood efficiently. Over time, this can strain the heart and affect overall health.

Common signs of AFib include:

  • A fluttering or irregular heartbeat
  • A sensation that the heart is racing or skipping beats
  • Fatigue or feeling unusually tired
  • Shortness of breath
  • Dizziness or lightheadedness
  • Chest discomfort or pressure

Because these symptoms can show up gradually, many people don’t connect them to a heart condition. In fact, according to the Medtronic-sponsored survey, one in four people said they wouldn’t take recurring symptoms like heart fluttering or fatigue very seriously, even if they lasted for months.

“The survey findings are a wake-up call—too many people haven’t heard of AFib or don’t recognize its symptoms as something worth acting on,” says Khaldoun Tarakji, MD, MPH, Vice President of Medical Affairs and Chief Medical Officer of Cardiac Ablation Solutions at Medtronic. “By recognizing the early signs and talking with a healthcare provider, people have a better chance of managing AFib before it leads to more serious complications.”

Take Control with New AFib Treatments

Medications have long been the first choice for treating AFib, but they don’t work for everyone. In fact, about half of patients find that medications either don’t fully relieve their symptoms or cause unwanted side effects.5-7

Newer, less invasive treatment options – like ablation procedures – are becoming more widely available, yet many people don’t know they exist.3 Despite their effectiveness, more than half of Americans have never heard of ablation procedures. One promising approach, called pulsed field ablation, uses short, controlled bursts of electrical energy to correct the heart’s rhythm without damaging nearby healthy tissue. This treatment can be used alongside medications or, in some cases, as an alternative.

If you’ve been experiencing ongoing fatigue, heart flutters, or shortness of breath, don’t ignore these symptoms. Talk to your doctor about what you’re feeling and explore all the treatment options that might help you feel better.

To learn more about AFib and pulsed field ablation, visit Medtronic.com/Afib.

References

  1. Roth GA, Mensah GA, Johnson CO et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol 2020;76:2982-3021.
  2. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112:1142–1147.
  3. Medtronic Data on File. Morning Consult. 2025. National Tracking Poll on Atrial Fibrillation Awareness. Sponsored by Medtronic. Online Survey, n= 2202. August 16–18, 2025.
  4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. August 1991;22(8):983-988.
  5. Andrade JG. Ablation as First-line Therapy for Atrial Fibrillation. Eur Cardiol. 2023;18: e46. 
  6. Al-Jazairi MIH, Nguyen BO, De With RR, et al. Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 study. Europace. 2021;23(9):1359-1368. 
  7. Valembois L et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database of Systematic Reviews 2019, Issue 9. Art. No.: CD005049.  

 

This content was published with support from Medtronic.

 

About the Medtronic-Sponsored Survey:

Medtronic engaged Morning Consult to conduct a nationally representative survey to gain insights into consumer perceptions and awareness of atrial fibrillation and related treatment options. The survey was deployed among 2,200 U.S. adults between August 16 and August 18, 2025, using an online survey.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.